Back pain isn't showing up in your productivity numbers
43.8% of UK workers are living with joint or muscle pain, and three quarters of them have been for more than two years. The cost is leaking out through sickness absence and presenteeism, not through self-reported performance, which is where most organisations are looking.
For most of the last decade, workplace musculoskeletal health has been treated as an occupational health question, owned at the individual level, addressed at the desk-assessment level, and supported when someone asks for it. The conversation has moved on substantially for mental health, which is now firmly on the leadership agenda for most large organisations. The conversation about MSK pain has stayed roughly where it was.
That position is becoming untenable. Across 35,837 health assessments completed insied the Champion Health platform, by working adults between 2021 and 2025, 43.8% of the workforce reported living with joint or muscle pain. The most affected site by some margin is the lower back at 27.6%, followed by the knee at 16.9%, the neck at 12.4%, and the shoulder at 12.3%. Nearly three in ten rate their pain as severe. The median duration is two years, and 75.9% have been living with the same pain for two years or more. More than half have never sought specialist treatment.
This is a workforce that has been quietly carrying pain for a long time, and the way most organisations measure productivity is not picking it up.
The cost the productivity numbers aren't showing
The productivity story for MSK pain is unusual. When workers complete a Champion Health assessment, the self-reported productivity gap between those with and without pain is essentially negligible. Pain sufferers do not report doing meaningfully worse work than their pain-free colleagues.
The cost shows up elsewhere. Pain sufferers take 51% more sickness days than those without pain, at an average of 3.43 days versus 2.27 days. They are 19% more likely to take any sickness absence in the year (37.2% versus 31.3%). And they are 57% more likely to be in the long-term absence cohort, taking eleven or more days off (7.1% versus 4.5%).
The most consistent explanation for this pattern is presenteeism. People are showing up. They are also tired, slept poorly, and sore, and they are doing the work against a higher baseline of strain. Workers reporting pain are 14.2 percentage points more likely to also report low energy, and 12.2 percentage points more likely to report poor sleep. The stress gap is smaller but still present at 4.7 percentage points. We cannot say from this data which direction causality runs (pain disrupts sleep, and poor sleep amplifies the experience of pain, with both probably happening), but the conditions travel together consistently, and organisations measuring only self-reported productivity are looking at the wrong end of the cost.
The external picture is consistent with what we are seeing in the workforce data. HSE's 2024/25 statistics show that 7.1 million working days were lost to musculoskeletal disorders in Great Britain, with back-related conditions alone accounting for 41% of all MSD-related days lost. Wider UK research estimates that back pain costs the economy around £3.8 billion in lost productivity each year, with a total economic burden of £10 to £12 billion once NHS care and welfare costs are included. Over 60% of UK organisations report musculoskeletal disorders as their primary cause of long-term absence. None of those headline figures fully captures presenteeism, staff turnover linked to poor health, or the well-documented tendency to under-report absence in self-reported data. The real cost to employers is likely to be higher again.
What changes when MSK pain is treated as a workforce health risk
Three things shift. Measurement broadens from self-reported productivity to absence patterns, age and work-type variation, and overlap with other health conditions, because that is where the cost is actually showing up. Ownership moves from individual occupational health to workforce health strategy, because the prevalence is too high to be handled case by case. And intervention moves earlier in the cycle, toward the protective behaviours and environmental factors that are measurable before the pain becomes long-term, rather than the desk assessments and specialist referrals that follow.
What individuals can do
If you are recognising the experience of long-running joint or muscle pain in your own working life, the most useful starting point is to notice what the data is most consistent about. Strength training has the strongest protective association with MSK pain in the dataset. Workers doing two or more sessions per week report pain at 38.0%, compared to 47.1% among those doing none. That is not a marginal difference. Over a third of the workforce currently does no strength training at all, and the cohort that would benefit most, workers aged 55 to 64 where pain prevalence reaches 57%, has the lowest participation rate at 25.4%.
The other consistent finding is sleep regularity. An irregular sleeping pattern is the single strongest lifestyle predictor of poor sleep quality in this dataset, with a 28.7-percentage-point gap between regular and irregular sleepers. For workers carrying pain, where sleep is already under pressure, the protective effect of a consistent schedule compounds. Small, sustainable changes outperform larger but inconsistent ones.
If you are not currently carrying pain, the most useful step is to assume that around four in ten of your colleagues are, and that most of them are not talking about it. Workplaces that are quiet about MSK pain are not pain-free workplaces. They are workplaces where the conversation has not yet started.
What organisations can do
Three things tend to separate organisations that act on MSK pain at workforce level from those that handle it case by case.
The first is measurement. Self-reported productivity scores will not catch the cost. Absence pattern data, broken down by health condition, work type, and age, will. Healthcare workers report the highest pain prevalence at 52.6%, followed by home-based workers at 46.8%. If you do not know where MSK pain is concentrating in your workforce, you cannot prioritise where to invest.
The second is treating MSK pain and mental health together. The data is consistent that these conditions compound. Workers carrying both lose more than four times the absence days of those carrying neither. Strategies that address only one stream miss the most expensive cohort by design, and that cohort is large.
The third, and the one most organisations underestimate, is visibility ahead of intervention. MSK pain develops over months and years, not days. By the time it shows up in an absence pattern, the protective behaviours that would have made the most difference, including consistent movement, strength training, and sleep regularity, have usually been absent for a long time. Workforce health data that surfaces the risk earlier creates a different conversation, and a much cheaper one.
A note on where to start
If you are an HR or People leader, the most useful place to begin is with a question about your own absence data. Where is sickness absence concentrating, and how much of it is health-related strain that has been building long before it became an absence at all? The cost of asking that question is low. The cost of not asking it, given that musculoskeletal disorders alone accounted for 7.1 million lost working days last year, is not.
If you are an individual recognising this in your own working life, the most useful step is the smallest one. Talk to one person about it. Look at the basics: consistent sleep, regular movement, and a small amount of strength work. None of it is dramatic, and the data is consistent that those are the levers that move most.
The findings in this article are a small preview of the Champion Health Workplace Health Report 2026, which draws on five years of data across 35,837 assessments and looks at how mental health, burnout, musculoskeletal pain, belonging, and financial wellbeing compound across the workforce.
At Champion Health, we work with organisations to give leaders visibility into where workforce health risk is building, including the strain that is not yet showing up in absence figures, and to give individuals the tools to act earlier. If you would like to explore what that could look like in practice, we would love to talk.
Sources
- Health and Safety Executive (2025). [Health and safety statistics for Great Britain 2024/25](https://www.hse.gov.uk/statistics/overview.htm).
- Health and Safety Executive (2025). [Working days lost in Great Britain](https://www.hse.gov.uk/statistics/dayslost.htm).
- Chartered Management Institute. [Chronic pain is costly to both its sufferers and the wider economy](https://www.managers.org.uk/knowledge-and-insights/advice/chronic-pain-is-costly-to-both-its-sufferers-and-the-wider-economy-how-can-managers-help/).
- Parallel Employee Benefits (2025). [The £3.8 Billion Problem Employers Can't Ignore: Back Pain at Work](https://www.parallel-eb.co.uk/2025/09/back-pain-at-work/).
- The European Business Review. [UK Musculoskeletal Crisis Costs NHS Billions](https://www.europeanbusinessreview.com/uk-musculoskeletal-crisis-costs-nhs-billions-custom-rehab/).